Cat. #151437
Anti-Leu2 [BU88]
Cat. #: 151437
Sub-type: Primary antibody
Unit size: 100 ug
Availability: 3-4 weeks
Target: Leu2 (CD8)
Class: Monoclonal
Application: FACS ; IHC
Reactivity: Human
Host: Mouse
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Roy Jefferis
Institute: University of Birmingham
Tool Details
*FOR RESEARCH USE ONLY
- Name: Anti-Leu2 [BU88]
- Clone: BU88
- Tool sub type: Primary antibody
- Class: Monoclonal
- Conjugation: Unconjugated
- Strain: Balb/c
- Reactivity: Human
- Host: Mouse
- Application: FACS ; IHC
- Description: BU88 may be used for the detection of immunoregulatory T cell subset imbalance in autoimmune and immunodeficiency states, categorisation of T cell acute lymphoblastic leukaemia and lymphoblastic lymphoma and T4/T8 ratios in rheumatoid arthritis, multiple sclerosis, etc.
- Immunogen: CD8 enriched peripheral blood lymphocytes
- Isotype: IgG1
- Myeloma used: P3/NS1/1-Ag4.1
Target Details
- Target: Leu2 (CD8)
- Target background: Leu-2 is a T cell co-receptor that recognises, together with the T cell receptor, MHC class I molecules. Leu-2 is present on human suppressor / cytotoxic T cells, 30% of circulating T cells.
Applications
- Application: FACS ; IHC
Handling
- Format: Liquid
- Concentration: 0.9-1.1 mg/ml
- Unit size: 100 ug
- Storage buffer: PBS with 0.02% azide
- Storage conditions: -15° C to -25° C
- Shipping conditions: Shipping at 4° C
References
- Kishimoto T. et al. (Eds.) 1997. Leukocyte Typing VI. Garland Publishing Inc. ISBN-13: 978-0815327455
- Leukocyte Typing VI. Kishimoto T. et al. (Eds.), Garland Publishing Inc. (1997)
- Langermans et al. 2000. J Med Primatol. 29(6):397-401. PMID: 11168830.
- Reactivity of human T-lymphocyte-specific antibodies with peripheral blood mononuclear cells and spleen of Aotus azarae ssp. boliviensis (owl monkey).
